Binding of urokinase-type plasminogen activator (uPA) t o its glycosylphosphatidylinositol-anchored receptor (uPAR) initiates signal transduction, adhesion, and migration in certain cell types. To determine whether some of these activities may be mediated by associations between the uPAl uPAR complex and other cell surface proteins, w e studied the binding of complexes composed of recombinant, soluble uPA receptor (suPAR) and single chain uPA (SCUPAI t o a cell line (LM-TK-fibroblasts) that does not express glycosylphosphatidylinositol (GPI)-anchored proteins t o eliminate potential competition by endogenous uPA receptors. scuPA induced the binding of suPAR t o LM-TK-cells. Binding of labeled suPARlscuPA was inhibited by unlabeled complex, but not by scuPA or suPAR added separately, indicating cellular binding sites had been formed that are not present in either component. Binding of the complex was inhibited by low molecular weight uPA (LMW-uPA) indicating exposure of an epitope found normally in the isolated B chain of t w o chain uPA (tcuPA), but hidden in soluble scuPA. Binding of LMW-uPA was independent of its catalytic site and was as-ROKINASE (UPA) IS A serine protease that is synthe-U sized and secreted as a single chain molecule, scuPA.
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scuPA expresses little enzymatic activity until it binds to its cellular receptor.' This receptor (uPAR) is a 3 13-amino acid three domain polypeptide that binds to plasma membranes through a glycosylphosphatidylinositol (GPI) anchor.' scuPA in solution or bound to its receptor can be converted by plasmin and kallikrein'.4 to a two-chain molecule (tcuPA) that retains enzymatic activity. tcuPA is a multidomain pro-sociated with retention of its enzymatic activity. Additional cell binding epitopes were generated within suPAR itself by the aminoterminal fragment of SCUPA, which itself does not bind t o LM-TK-cells. When scuPA bound t o suPAR, a binding site for a,-macroglobulin receptor/LDL receptor-related protein (a,MR/LRP) was lost, while binding sites for cell-associated vitronectin and thrombospondin were induced. In accord with this, the internalization and degradation of cellassociated tcuPA and tcuPA-PAl-1 complexes proceeded less efficiently in the presence of suPAR. Further, little degradation of suPAR was detected, suggesting that cell-bound complex dissociated during the initial stages of endocytosis. Thus, the interaction of scuPA with its receptor causes multiple functional changes within the complex including the disappearance of an epitope in scuPA involved in its clearance from the cell surface and the generation of novel epitopes that promote its binding t o proteins involved in cell adhesion and signal transduction. 0 1996 by The American Society of Hematology.
tein that consists of a catalytic domain, also known as the B chain or low molecular weight urokinase, and a noncatalytic aminoterminal fragment (ATF, amino acids 1-143). The aminoterminal fragment is itself composed of a single kringle, the function of which is unknown, and a growth factorlike domain (GFD, amino acids 4-43), which mediates its binding to uPAR.~
The interaction of uPA with its cellular receptor has been implicated in several extracellular activities including plasminogen activation,'.'.' matrix degradation," cell adhesion,".' ' and cell migration"-I5 during which uPA receptors may become polarized in the membrane. ''-" In addition, the interaction between uPAR and uPA is involved in several processes that require intracellular signaling, such as mitogene~is'~~" and cellular differentiati~n.'~.~' Several of these activities involve the catalytic activity of uPA, such as plasminogen activation and extracellular proteolysis, while others can be mediated by its aminoterminal fragment or even by the growth factor which suggests noncatalytic portions of the uPA molecule are involved.
The mechanism by which uPA initiates such intracellular activities in the absence of proteolysis is unclear. There is evidence that binding of scuPA to its receptor alters the function of the resultant complex,' possibly as a result of conformational changes that may also initiate signalling through its GPI anchor." An alternative explanation is that the conformational changes that occur when scuPA binds to uPAR may also induce novel interactions between the extracellular portions of the complex and other membrane components that have transmembrane associations.*'-'' In the present study, we provide evidence that binding of scuPA to its receptor induces epitopes in both proteins that promote binding of the complex to cellular integrin ligands. These changes are accompanied by the disappearance of a preex-
Ligand binding assays.
of rRAP, which inhibits the binding of all known ligands to a2MR/ LRP. Chilled and washed cells were preincubated for 1 hour at 4°C with the designated concentrations of rRAP in the presence of 4 mmoVL CaCI, ? 9 The preincubation solution was removed, the radiolabeled ligands were added in the presence of the same concentration of rRAP, and binding was measured as described above. As a second approach, the binding of '"I-wPAR and "'I-suPAIUSCUPA complexes to CHO cells lacking azMR/LRP"2 and binding to wild type CHO cells were compared. The abbreviations used are: uPA, urokinase-type plasminogen activator; scuPA, single chain uPA; tcuPA, two chain urokinase; ATF, aminoterminal fragment of urokinase; GFD, growth factor domain of urokinase; uPAR, urokinase receptor; suPAR, recombinant soluble urokinase receptor; PAI-1, plasminogen activator inhibitor type 1; GPI, glycosylphosphatidylinositol; aZMR/ LRP, a2--macroglobulin receptorflow density lipoprotein related receptor; rRAP, recombinant 30 kD a ' -macroglobulin receptor-associated protein; PI-PLC, phosphatidylinositol-specific-phospholipase C; Vn, vitronectin; TSP-1, thrombospondin-1; PBS, phosphate-buffered saline; TBS, Tris-buffered saline. As a third approach, the binding of '''I-SCUPA and '*'I-scuPA/suPAR to immobilized a2MR/ LRP was compared (see below). Second, the role of integrin ligands was examined in several ways. Chilled and washed cells were preincubated for 1 hour at 4°C with the designated concentrations of affinity-purified polyclonal antibodies to human fibronectin, vitronectin (Vn) or thrombospondin-1 (TSP-1) or with control rabbit Ig. The cells were washed and radiolabeled ligands were added in the presence of the same concentration of each Ig. As a second approach, LM-TK-cells were grown for 24 hours on fibronectincoated plates in 10% normal human serum or serum immunodepleted of vitronectin using an affinity-purified antivitronectin antibody and the binding of ' z ' I -~~P A R /~~~P A complexes was measured in parallel. As a third approach, LM-TK-cells (50 X IO4 cellskondition) were disadhered with trypsinEDTA as above, washed twice with DMEM, and incubated with DMEM in the presence or absence of EDTA ( 12 mmoVL final concentration) for 7 minutes. The cells were centrifuged, the pellet was resuspended in 50 pL PBS containing 1% bovine serum albumin (BSA) and either 12 mmolL EDTA, 500 pmoVL Ca++ or 500 p m o m Ca++ plus 140 nmoVL TSP-1, and the binding of suPAR/''51-scuPA was determined. To determine whether EDTA caused Vn or TSP-I to elute from cellular integrin~;~ the cell suspension was washed three times in Ca"-free PBS and incubated serially with limiting dilutions of anti-Vn or anti-TSP-1, biotinylated anti-Ig (Sigma), streptavidin horse radish peroxidase (Sigma) and o-phenylene diamine (Zymed, San Francisco, CA) and the optical density at 480 nm (0.D.480) was measured.
A 96-well microtiter plate was incubated with azMR/LRP (2 mg/well) in coating buffer (TBS containing 0.05% Tween-20, 3% BSA, 4 mmol/L CaCI,) for 18 hours at 4°C. The coating solution was removed and the unreactive sites were blocked with 3% BSA in TBS for 1 hour at room temperature. After aspirating the blocking solution, 4 nmoVL ''SI-scuPA or SUPAR/'~'IscuPA was added to each well in the presence or absence of 50-fold molar excess cold competitor for 4 hours at room temperature. The plates were washed four times in TBS containing 0.05% Tween 20, the residual radioactivity was solubilized in 0.1 N NaOH and counted. LM-TK-cells were incubated for 24 hours at 37°C with '251-t~~PA or '2'I-tcuPA-PAI-1, the same ligand complexed with suPAR or with '2'I-~~PAR alone or complexed with scuPA, tcuPA or tcuPA-PAI-I. The supernate was removed, placed on ice, and trichloracetic acid was added (final concentration 20%). After centrifugation, the acid-soluble counts were determined as a measure of total degradation. TCASolidphase binding assay.
Intemalization and degradation of SUPAWUPA.
For personal use only. on October 27, 2017. by guest www.bloodjournal.org FromsuPAR suPAR/scuPA scuPA soluble radioactivity measured in the absence of cells was subtracted to determine cell-specific degradation.
RESULTS
Binding of uPA to its receptor has been implicated in cell adhesion and signal transduction across the cell membrane. The fact that uPAR is a GPI-anchored protein raises the possibility that some of these biologic effects are mediated through interactions of the receptor or its bound ligand with other cell surface proteins that have transmembrane associations. To examine this possibility, we analyzed the interaction between '2'I-labeled suPAR and LM-TK-cells that do not express uPA receptors on their plasma membrane. These cells were chosen to exclude the possible occupation of potential uPA binding proteins by endogenous uPA receptors.
Complexes between ' 2 s I -~~P A R and scuPA bound to LM-TK-cells (Fig 1) . Binding reached a plateau by 90 minutes (Fig 2) . The total amount of complex bound was the same regardless of which component was labeled (not shown) suggesting that both ligands bind to the cells as a complex. A series of experiments were then performed to identify the binding sites in the suPAWscuPA complex that are involved in this binding and the identity of the cellular binding site or sites.
To address the first question, we began by asking whether the binding of suPAWscuPA complexes could be accounted for solely by its individual components. ''51-suPAR added alone did not bind to LM-TK-cells (Fig 1) . Further, '"IscuPA showed little binding to these cells, which lack endogenous uPAR, but binding was stimulated approximately fourfold by suPAR. The same fold increment was seen when natural soluble uPAR was studied (not shown). The same relative increase in binding was also seen when cells in suspension were studied (not shown), suggesting binding was to the cell surface and not to subcellular matrix. These results suggest that the suPAWscuPA complex contains additional binding sites not found within its components. In support of this interpretation, binding of labeled complex was inhibited approximately 65% by a 100-fold molar excess of unlabeled complex, but was unaffected by the same concentrations of unlabeled suPAR or scuPA added individually (Fig 3) . These results suggest that binding of scuPA to suPAR -20 ! suPAR/proUK proUK suPAR induces conformational changes in one or both components to form a novel cellular binding epitope. To address the nature of this site, we took advantage of a recent finding that the binding of scuPA to suPAR markedly increases its catalytic activity, suggesting a conformational change in the nascent B chain.' Therefore, we asked whether low molecular weight urokinase (LMW-uPA), which contains this catalytic domain, but does not bind to uPAR, would inhibit the binding of suPAWscuPA complexes. Indeed, LMW-uPA was a potent inhibitor of the binding of suPARIscuPA, while the intact scuPA molecule was not (Fig 4) . In addition, I2'I-LMW-uPA bound specifically to LM-TK-cells (Fig 5) . Nei- ther the binding nor the inhibitory capacity of LMW-uPA was affected by the active site inhibitor ameloride and cellbound LMW-uPA retained its amidolytic activity (not shown). Amiloride had no effect on the binding of suPARI scuPA. Taken together, these data indicate that suPAR induces a cellular binding epitope to be expressed in scuPA, which is normally found in the B chain of two-chain uPA, but which is hidden in soluble scuPA. Further, this cell binding epitope is distinct from the catalytic site.
We then asked whether cellular binding epitopes were also induced within suPAR as a result of complex formation. To address this question, we examined the effect of proteolytic fragments of scuPA on the binding of '"I-SUPAR. The aminoterminal fragment of scuPA, which by itself was unable to bind to LM-TK-cells (Fig 6) , induced the binding of suPAR, although not to the same extent as scuPA, which contains the potential binding site in the B chain. Indeed, even the growth factor domain of scuPA was able to increase the binding of '2sI-~~PAR to some extent (Fig 6) . These data suggest that changes also occur within the receptor itself when scuPA binds, which promotes its binding to LM-TKcells.
The next series of experiments were designed to identify the cellular sites to which suPAR/scuPA bound. To address this issue, we first characterized the binding kinetics of the complex. The specific binding isotherm did not follow a simple hyperbolic function. Rather, increasing the concentration of suPAR/scuPA resulted in a sigmoid binding curve (Fig 7) . Analysis of binding using a double reciprocal plot shows a nonlinear pattern, suggesting, among other possibilities, positive cooperativity between binding epitopes within the complex or the participation of more than one cellular site (not shown). These possibilities were further considered.
For
[ Ligand ] nM scuPA is known to bind directly to a2MRILRP.""' Therefore, we began by asking whether the suPAWscuPA complex also bound to a2MRILRP by comparing the effect of rRAP on the binding of each ligand. ing of scuPA to LM-TK-cells was inhibited 76% by rRAP (200 nmol/L), while the binding of suPAWscuPA was essentially unaffected both at this concentration and at concentrations of rRAP as high as 800 nmol/L (not shown). Moreover, in a cell-free system, preincubation of '2'I-scuPA with su-PAR inhibited its binding to purified a2MWLRP by 86%. The possibility remained that the failure of rRAP to inhibit binding of suPAWscuPA was due to a marked increase in its affinity for cellular a2MR/LRP or by binding of complex to a rRAP-insensitive site(s). Therefore, we compared the binding of scuPA, suPAR, and suPAWscuPA complexes to a mutant C H 0 cell line'' that expresses GP!-linked uPAR, but does not express a2MR/LRP. Binding of 12SI-suPAW scuPA to this a2MR/LRP-deficient cell line was comparable to the binding of complexes to native CH0 (Fig 9) . In other experiments, endogenous uPAR was blocked by preincubating these cells with PI-PLC and by adding 50-fold mol/L excess unlabeled ATF (200 nmol/L). Binding of ''SI-scuPA/ suPAR to these a,MR/LRP-deficient cells was 16-fold greater than the binding of scuPA (not shown). These data exclude a2MR/LRP as the predominant site of binding and suggest that the induction of binding sites in scuPA for LM-TK-cells by suPAR is associated with the loss of other sites for a2MR/LRP.
We next considered whether suPAWscuPA bound to each of several surface proteins that have been reported to bind uPA and have been implicated in cell adhesion and signal transduction, such as fibronectinZx and vitronectin." Binding of suPAWscuPA to LM-TK-cells was unaffected by a polyclonal affinity purified antifibronectin antibody (Fig IO) . We next asked whether the complexes bound to vitronectin, which has also been reported to bind scuPA."' Preincubation of LM-TK-cells with each of two distinct affinity-purified polyclonal antivitronectin (Vn) antibodies reduced the binding of suPAR/scuPA by a mean of 54%, while normal rabbit serum had no effect (Fig 10) . Binding of suPAR1scuPA was also reduced by approximately 50% when the LM-TK-cells were grown in human serum immunodepleted of Vn.
The fact that binding of suPARJscuPA to vitronectin could not account for all the binding to LM-TK-cells and the kinetic analysis shown in Fig 7 together suggest the involvement of a second cellular site. Therefore, we next considered the possibility that an interaction between suPARlscuPA and thrombospondin (TSP-I), which has been reported to bind tcuPA in purified systems:' could account for the remaining cellular sites. Compatible with this hypothesis, polyclonal anti-TSP-l antibody inhibited the binding of suPARJscuPA to LM-TK-cells by 46% (Fig IO) . The inhibitory effects of anti-Vn and anti-TSP-I antibodies were additive and together almost totally blocked suPARJscuPA binding (Fig  IO) . The involvement of TSP-I was then examined in more detail. Preincubation of LM-TK-cells with 12 mmollL EDTA, which is known to alter the structure and function decreased the binding of suPAR1scuPA by more than SO% (Fig 11) without causing TSP-I (or vitronectin) to dissociate from the cells as determined by enzymelinked immunosorbent assay (ELISA). Addition of Ca++ (SO0 pmolIL final concentration) restored binding to approximately 88% of its initial level in the presence or absence of additional TSP-I. We then asked whether the complex bound to TSP-I through the site induced in scuPA shared with LMW-uPA. In accord with this possibility, anti-TSP-I antibody inhibited the binding of "'I-LMW-uPA to LM-TK-cells 63%, while anti-Vn had no inhibitory effect (Fig   12) .
As a final question, we asked whether the binding of suof TSP-I4'.'9''3 PAWscuPA to cell-associated Vn and TSP-I altered the internalization and degradation of either component of the complex. Since the results shown in Fig 8 indicate that scuPA bound to suPAR lost its capacity to bind to a2MW LRP, these measurements were made using complexes between suPAR and tcuPA and suPAR and tcuPA bound to plasminogen activator inhibitor type 1 (PAI-l). A small amount of tcuPA was degraded by LM-TK-cells, suggesting internalization of the ligand via a2MR can occur without requiring prior binding to uPAR, as previously reported.JJ,"5
Further, approximately fourfold more tcuPA was degraded following the addition of PAI-l, as expected (Fig 13) . However, the internalization and degradation of both tcuPA and tcuPA-PAI-l proceeded less efficiently in the presence of suPAR. Specifically, although suPAR increased the capacity of tcuPA to bind to LM-TK-cells almost fourfold (see Fig  I) , a slight reduction in the total amount of tcuPA degraded was seen, and the degradation of tcuPA-PAL1 was decreased by -25% (Fig 13) . Further, little if any, suPAR was degraded whether added alone or when preincubated with tcuPA (Fig 13) . Even when radiolabeled suPAR was bound to tcuPA-PAI-1, only 13% as much '*'I-suPAR as '"ItcuPA was degraded when measured in parallel.
DISCUSSION
The observation that scuPA and its aminoterminal fragment alter the adhesion and differentiation of some cell types suggests changes occur within occupied uPA receptors that initiate signal transduction through its GP1 anchor and/or that formation of a complex between scuPA and uPAR modulates its interaction with other cell surface components. The results of the present study provide support for the latter hypothesis.
'251-labeled soluble uPA receptor did not bind to LM-TKcells, while the same protein acquired the capacity to bind when preincubated with unlabeled scuPA. The specificity of this interaction is shown by the fact that binding was inhibited by unlabeled suPAR preincubated with scuPA. Identical results were obtained when the radiolabel was present on the scuPA molecule, indicating that suPAWscuPA bound as a l:! stoichiometric complex. The complete inability of either suPAR or scuPA by themselves to compete with suPAW scuPA for binding provides evidence that these complexes have acquired new epitopes that do not preexist in either component. Additional support for this conclusion comes from the observation that suPARIscuPA binds more extensively than does scuPA alone and that suPAR is unable to bind to LM-TK-cells in the absence of ligand. The existence of novel binding sites within the complex is also suggested by the fact that while neither suPAR nor the aminoterminal fragment of scuPA bind to LM-TK-cells under the experimental conditions, complexes between suPAR and ATF bind, and this binding is not inhibited by suPAR or scuPA alone.
Our data suggests that the binding of suPAWscuPA to LM-TK-cells involves conformational changes in both molecules. On one side of the complex, binding of scuPA to suPAR exposes a site, which is expressed in LMW-uPA, but which is partially hidden in soluble scuPA itself. This is consistent with previous observations that binding of scuPA to suPAR enhances its enzymatic activity.' However, the site on the B chain involved in binding is independent of the catalytic triad since binding of both LMW-uPA and suPAW scuPA was unaffected by addition of an active site titrant, and cell-associated LMW-uPA retains enzymatic activity. On the other side of the complex, the amino terminal fragment of uPA induces the binding of suPAR, but by itself, is unable to bind to the cells or to inhibit the binding of suPARJ scuPA complexes.
In addition to generating novel cellular binding epitopes, formation of suPARIscuPA complexes lead to the loss of preexisting interactions of scuPA with a,MR/LRP. In support of this, rRAP inhibited the binding of scuPA to LM-TK-cells, but not the binding of suPAWscuPA complexes. Moreover, suPAR inhibited the binding of scuPA to immobilized a2MR/LRP, in accord with previously reported observations? The fact that scuPA is less able to bind to a2MW LRP and suPAR simultaneously means that the SCUPNSU-PAR complex must develop epitopes that permit it to bind to other sites on the cell surface. The strongest evidence for the existence of such sites is the binding of suPARIscuPA complexes to a C H 0 cell line lacking a,MR/LRP.
Our results provide evidence that two of the involved sites are vitronectin and thrombospondin and, further, that the suPARIscuPA complex can bind independently to each protein. In support of this, we found that antibodies to Vn inhibited the binding of suPAWscuPA approximately 50%. as did immunodepleting plasma of this protein. Binding of the complex was also inhibited to the same extent by antibodies to TSP-l, while a combination of anti-Vn and anti-TSP-l antibodies inhibited binding almost completely. Consistent with the involvement of both integrin ligands, chelation of Ca++, which disrupts the structure and function of TSP-I, For personal use only. on October 27, 2017. by guest www.bloodjournal.org From but not that of Vn,43*49-53 inhibited suPARIscuPA binding -50%. However, our results do not exclude the possibility that suPAWscuPA may bind to additional sites in some cell
The loss of a binding epitope in SCUPA for a2MR/LRF' by suPAR in association with the induction of binding sites for vitronectin and thrombospondin has, as one consequence, an apparent decrease in the rate of scuPA internalization and degradation. This decrease is not likely to result from competition between Vn, Tsp, and a,MRLRP for the same site(s) on receptor-bound scuPA, since the binding of scuPA to purified a2MR/LRP was almost totally inhibited by suPAR when neither integrin ligand was present. Rather, binding of the complex to Vn and Tsp may cause the complex to bind to sites where it is physically less accessible to a2MR/LRP or the integrin ligands may restrain the mobility of receptorbound scuPA in the cell membrane. In support of the latter possibility, only one tenth as much receptor as scuPA was degraded. This result suggests that the soluble complex may dissociate before or during the initial stages of endocytosis, although the possibility that suPAR is degraded less efficiently in lysosomes cannot be formally excluded by our studies. The point at which tcuPA-PAI-1 complexes dissociate from endogenous GPI-anchored uPAR and the role of the anchor in protecting uPAR from lysosomal degradation requires further study." Our data support the observations of Wei et all' that suPAR/scuPA complexes bind to immobilized vitronectin. However, in contrast to their findings using urea-treated or immobilized vitronectin, we did not observe a direct interaction of suPAR with vitronectin on the surface of LM-TK-cells under the conditions of our experiments. Further, our data indicate that the conformational change that develops in scuPA is an obligatory part of this interaction with the cell surface, since LMW-uPA inhibited binding of suPARIscuPA complexes by >80%. Moreover, we observed additional complexities that occur as a result of complex formation in this cell type with an increase in binding to thrombospondin, a loss of binding to a,MR/LRP, a decrease in scuPA degradation, and a dissociation of scuPA from its receptor during the internalization process.
In summary, the results of the present study indicate that binding of scuPA to its receptor induces conformational changes in both molecules, which transforms the resultant catalytically active complex' into a ligand for other proteins as well. This may represent a mechanism by which the uPA receptor apposes an enzyme involved in matrix degradation with potential substrates at sites of while at the same time retarding its intemalization and degradation by c~~MR/LFW."~ The GPI anchor on uPAR may serve to maintain high local concentrations of such complexes on the cell surface while permitting them to interact efficiently with other cell surface proteins, some of which participate in uPAmediated cell adhesion and signal transduction, while others contribute to the polarized expression of uPA receptors on migrating cells. For personal use only. on October 27, 2017. by guest www.bloodjournal.org From
